Myelodysplastic Syndromes News and Research

RSS
Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

LLS announces four new Academic Concierge partnerships for cancer drug development

LLS announces four new Academic Concierge partnerships for cancer drug development

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec reimburses VIDAZA for treatment of blood cancer

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

MDS Foundation: Significant advances made in understanding, treating MDS, AML

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML